Related Experiment Videos
ACE inhibitors in vascular disease: some PROGRESS, more HOPE
1University Department of Medicine, City Hospital, Birmingham B18 7QH, UK. g.y.h.lip@bham.ac.uk
Journal of Human Hypertension
|January 5, 2002
Abstract
No abstract available in PubMed .
Related Concept Videos
Articles linked to this work by shared authors, journal, and citation graph.
Matrix metalloproteinases and their tissue inhibitors in hypertension-related pregnancy complications.
Journal of human hypertension·2012
Do we need more long-term outcome trials for the treatment of hypertension?
The journal of the Royal College of Physicians of Edinburgh·2011
Left ventricular hypertrophy by Sokolow-Lyon voltage criterion predicts mortality in overweight hypertensive subjects.
Journal of human hypertension·2008
Ethnic differences in cancer incidence and mortality: the Birmingham Factory Screening Project.
QJM : monthly journal of the Association of Physicians·2007
Left ventricular hypertrophy determined by Sokolow-Lyon criteria: a different predictor in women than in men?
Journal of human hypertension·2006
The association between mobility and asleep blood pressure alterations in frail and non-frail adults 80 years and older.
Journal of human hypertension·2026
Beyond ad hoc home blood pressure monitoring: The need for standardisation and integration into primary care.
Journal of human hypertension·2026
Prevalence of hypertension in severe vs. non-severe COVID-19: a systematic review and meta-analysis.
Journal of human hypertension·2026
Triple drug antihypertensive single-pill combinations included as WHO essential medicines: an overview of efficacy, safety, and cost.
Journal of human hypertension·2026
Benzophenone Derivatives as a New Class of Anti-Infectives Against Acanthamoeba spp.
Archiv der Pharmazie·2026
Novel 1H-Indole-3-carboxamide Derivatives as CDK4 Inhibitors for Treating Cancer.
ACS medicinal chemistry letters·2026
Novel Heterocyclic Compounds for Treating HIV Infection.
ACS medicinal chemistry letters·2026
Novel 6,5-Bicyclic Compounds as 5‑HT2A Receptor Agonists for Treating Depression, Anxiety, Substance Abuse, and Headaches.
ACS medicinal chemistry letters·2026